Development Strategy Series — Article 3: Evidence Architecture
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Navigate Complex Decisions From Innovation to Impact | Development,
Development Strategy Series — Article 2: Why Good Science Isn’t Enough
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Navigate Complex Decisions From Science To Patient Impact |
Development Strategy Series — Article 1. Commercial Strategy: How Does Value Reach Patients?
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Navigate Complex Decisions From Science To Patient Impact |
A Cost Comparison Across Drug Development’s Three Hardest Arenas
Vaccines, oncology, and rare disease programs each carry distinct cost structures, attrition profiles, and funding dynamics. Understanding the differences serves
Playing to Win: How Competitive Intelligence Shapes Drug Development Strategy
Drug development is expensive, slow, and brutally competitive. A Phase 3 study failure costs hundreds of millions of dollars. A
Most Teams Prepare the Dossier. Few Prepare the Pathway.
When developing novel life science technologies, drugs, biologics, and gene or cell therapies, how often do early-stage teams conduct a
Why Regulatory Strategy Belongs in the Investment Thesis — Not the To-Do List
*A summary of Pathway Capital’s whitepaper on regulatory strategy in early-stage life science investment There is a gap in how